Table 1.
Baseline Characteristics of the MCL Patients With COVID-19 Infection
| Characteristics | All Patients (n = 63) | Deceased (n = 28) |
|---|---|---|
| Male (all patients), n (%) | 48 (76) | 24 (50) |
| Female (all patients), n (%) | 15 (24) | 4 (26.6) |
| Age (y), median (range) at infection onset | 64 (43–84) | |
| ≤65, n (%) | 32 (50.8) | 13 (40.6) |
| ≥65, n (%) | 31 (49.2) | 15 (48.3) |
| Current treatment at time of COVID-19 infection, n (%) | ||
| Induction/consolidationa | 23 (36.5) | 13 (56.5) |
| Rituximab maintenance | 15 (24) | 7 (47) |
| Novel drugsb | 15 (24) | 7 (47) |
| None | 6(9.5) | 1 (16) |
| Unknown | 4 (6) | 0 |
| Remission status at time of COVID-19 infection, n (%) | ||
| Responding (CR, PR)c | 44 (70) | 19 (43) |
| Active disease (SD, PD)d | 13 (21) | 7 (54) |
| Unknown | 6 (9) | 2 (33.3) |
| MCL treatment paused due to COVID-19 infection, n (%) | ||
| Yes | 6 (10) | 0 |
| No | 45 (71) | |
| Not applicable or unknown | 12 (19) | |
| Overall mortality, n (%) | ||
| Death due to COVID-19 infection | 24 (86) | 24 (86) |
| Death due to lymphoma | 3 (11) | 3 (100) |
| Death for other reasons/unknown | 1 (3.5) | 1 (100) |
| Days between COVID-19 infection and death (range) | 26 (1–344) | |
| COVID-19 disease course, n (%) | ||
| Ambulatory care for COVID-19 infection | 17 (27) | 0 |
| Hospitalization because of COVID-19 infection | 46 (73) | 28 (61) |
| Mild infectione | 29 (46) | 4 (13.7) |
| Severe infectionf | 34 (54) | 24 (70.5) |
| ICU admission | 16 (35) | 15 (94) |
| Median number of days of between infection and hospital admission (range) | 1.5 (0–365) | |
| Median number of days between hospitalization and death (range) | 22 (4–211) | |
| Time between hospital admission and discharge in days (range), n = 15 | 21.5 (4–66) | |
| Airway management in hospitalized patients (n = 46), n (%) | ||
| None | 9 (20) | 2 (22) |
| Nasal oxygen support | 17 (37) | 8 (50) |
| CPAP | 2 (4,4) | 2 (100) |
| Ventilator | 14 (30) | 13 (93) |
| ECMO | 1 (2) | 1 (100) |
| Unknown | 4 (89) | 2 (50) |
| COVID-19-specific treatment in all patients, n (%) | ||
| Corticosteroids | 27 (43) | 20 (71) |
| Antibiotics | 18 (,29) | 11 (39) |
| Remdesivir | 15 (24) | 10 (36) |
| Convalescent plasma | 12 (19) | 6 (21) |
| Virus monoclonal antibodies | 1 (2) | 1 (4) |
| Anti-IL6 treatment | 1 (2) | 1 (4) |
| COVID-19 sequelae in COVID-19 survivors (n = 35), n (%) | ||
| Reduced bone marrow function | 7 (20) | |
| Fatigue | 15 (43) | |
| Pulmonary toxicity acute/chronic | 4 (11)/3(9) | |
| Number of vaccinated patients | 9 (14.2) | 0 |
| COVID-19 infection after vaccination | 2 (22.2) | 0 |
aInduction: R-CHOP (6), R-Bendamustine (5), R-CHOP/R-HAD + ASCT (5), R-BAC (4); consolidation: Post allogeneic transplantation (2, one patient 52 d after TX, unknown for the other patient), R-BEAM + ASCT (1).
bNovel drugs: Ibrutinib (5), Lenalidomide (3), Ibrutinib+Venetoclax (2), Ibrutinib+Obinutuzumab (1), Ibrutinib+Rituximab (3), R² (Rituximab + Lenalidomide, 1).
cResponding patients: 48% CR (n = 30), 22% PR (n = 14).
dActive disease: 8% SD (n = 5), 13% PD (n = 8).
eMild infection = no need for hospitalization or hospitalization without need for oxygen therapy.
fSevere infection = need for hospitalization and oxygen therapy.
CPAP = continuous positive airway pressure; CR = complete remission; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; MCL = mantle cell lymphoma; PD = progressive disease; PR = partial remission; SD = stable disease.